Increasing the dose of Pn1-CRM197 in the i.n. booster yielded higher specific IgA levels in serum, saliva, and lung homogenates (Figure 5) and increased the proportion of mice reaching the protective levels of specific IgG Abs against bacteremia (Supplementary Table 2). Here, CD79A is linked to bacterial infectious disease with sepsis.